Arvinas logo
Close this search box.

About Us

Our Mission

To improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform.


Transforming the Future for Patients

Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins.

For people living with cancers and other difficult-to-treat diseases, our approach has the potential to be transformative. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.

Smiling Arvinas scientific staff member talking with colleague
Two people ascending stairs
Two Arvinas staff members reviewing data on computer monitor

We Are Undeterred by “Undruggable”

We’ve developed a broad technology platform focused on high-value targets to deliver more potent therapies and address the majority of proteins that evade inhibition—including those that have been deemed “undruggable” by traditional approaches.

Our lead programs are currently focused on the receptors associated with prostate and breast cancers.

At Arvinas, we work every day to unlock the full potential of PROTAC® protein degraders, developing a robust pipeline and partnering with the world’s leading drug development companies to bring new possibilities where they are needed most.

1O Years of Scientific Discovery


Arvinas is founded by Yale professor Craig Crews with the goal of turning PROTAC® protein degraders into patient therapies


Arvinas creates the first oral PROTAC® protein degraders for clinical trial evaluation


Arvinas creates the first blood-brain barrier-crossing PROTAC® protein degraders


Two Arvinas PROTAC® degraders, bavdegalutamide and vepdegestrant, enter clinical studies


Proof of concept is achieved for bavdegalutamide and vepdegestrant


Arvinas partners with Pfizer to co-develop and co-commercialize vepdegestrant

Arvinas PROTAC® degrader ARV-766 enters clinical studies


Arvinas initiates first registrational study with vepdegestrant


Arvinas begins clinical trials of ARV-102, an investigational PROTAC® protein degrader for neurodegenerative diseases


Arvinas licenses ARV-766 to Novartis 

Bavdegalutamide and vepdegestrant are currently under investigation. Their safety and effectiveness have not yet been established.

Smiling Arvinas scientific staff member talking with colleague
Arvinas scientific staff

If you’re inspired, please take a look at the current list of opportunities to join our team.


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content